A comprehensive analysis of product types, applications, customers and geography segments helps to identify the growth opportunities in the global antibody drug conjugate market.
Portland, OR -- (SBWIRE) -- 07/19/2017 -- Antibody drug conjugates (ADCs), also known as anti-cancer drugs are promising and effective modalities for cancer therapies. The ADCs are prepared by combining two principles i.e. monoclonal antibody specificity and cell killing efficacy of HPAPI (highly potent active pharmaceutical ingredient). This combinational approach specifically kills the cancer cells by a toxic payload through binding and internalizing ADC into the cancerous cells. Several years of extensive biological research and developments in the pharmaceutical sector have led to the development of the worlds first two ADCs namely Adcetris and Kadcyla for cancer therapy. The Antibody drug conjugates (ADCs) market is yet dormant as only two drugs are approved and commercialized till date. Adcetris from Seattle Genetics received the FDA approval in 2011 for the treatment of systemic anaplastic large cell lymphoma and Hodgkins lymphoma. Kadcyla, a product from Genentech, used in the treatment of breast cancer received the FDA approval in 2013.
"Early Buyers Will Receive 20% Customization on This Report."
Furthermore, the antibody drug conjugates market is highly potential market with about 27 drugs that are currently under different phases of clinical trials in both solid tumors indications and hematological malignancies. Thus, ADCs hold great opportunities in the field of pharmaceuticals owing to their novel nature and profound therapy modality in comparison to conventional treatments. Extensive R&D and rising incidences of various cancers are the key factors that drive the growth of this market. However, the high cost associated with research activities, stringent regulatory requirements and several challenges associated with the manufacturing of these drugs are restricting the growth of the Antibody drug conjugates market.
Get PDF Brochure @ https://www.alliedmarketresearch.com/request-toc-and-sample/1467
The global antibody drug conjugates market is segmented on the basis of approved drugs, drugs in pipeline and geography. Approved drugs are segmented into Adcetris and Kadcyla. Pipeline drugs consist of many drugs such as T-DM1, CMC-544, CDX-011, SAR3419 and many others. Geographically, the report is segmented into four regions viz., North America, Europe, Asia-Pacific and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Pfizer, Inc., Celldex Therapeutics Inc., Seattle Genetics, Genentech Inc., Immunogen Inc., Sanofi S.A., Immunomedics, Inc., Progenics Pharmaceuticals Inc., Bayer Healthcare Pharmaceuticals, Synthon and many others. Few of the key strategies adopted by the top market players include technological advancements and collaborations. The key manufacturers with their ADCs pipelined in clinical trial stages include Pfizer, Inc. - notuzumab Ozogamicin, Celldex Therapeutics - Glembatumumab Vedotin, ImmunoGen, Inc.-Lorvotuzumab Mertansine, Sanofi S.A. - SAR3419, Progenics Pharmaceuticals - PSMA-ADC and few others. All the aforementioned drugs are under clinical trial phase II.